SCA Pharma understands that the most effective 503B solution is a partner you can trust.
We work hand in hand with your management team to implement strategies that keep your pharmacy at the ready. From improving demand planning to optimizing inventory tracking and control, we make sure you have the medications you need, when you need them.
We are here for you. Experience the difference of outsourcing sterile compounding with a 503B outsourcing facility that’s got your back.
Redefining quality standards for 503B organizations requires a meticulous approach to everything we do. Explore our quality processes and protocols.
SCA Pharma’s diverse product catalog is constantly evolving to better serve the current and future needs of our client partners.
Team up with a nationally recognized leader in the FDA 503B outsourcing industry. SCA Pharma specializes in providing hospital and health-care facility pharmacies with the highest quality sterile admixture services and pre-filled syringes, including ready-to-use and drug-shortage medications.
Our two state-of-the-art sterile compounding facilities serve all therapeutic areas of pharmacy, including critical care, labor and delivery, anesthesia and pain management.
Take a look at our state-of-the-art facilities and get a glimpse of the steps in a product’s journey.
“As sterile outsourcing continues to gain traction within the pharmaceutical landscape, SCA Pharma’s key differentiator will be our continuous commitment to best-in-class quality and manufacturing. SCA Pharma is well-positioned for growth and innovation, and I take the company reins excited to leverage our relentless focus on quality and the customer experience.”
Discover industry insights and learn more about the people and innovations driving SCA Pharma.
SCA Pharma, a nationally recognized leader in the 503B compounding pharmaceuticals outsourcing industry providing quality, service, and value to hospitals nationwide, has announced today the addition of Louis Pace as Chief Financial Officer and Chief Information Officer. Pace brings over 30 years of experience serving several successful private equity backed businesses in functional and P&L…
Details
Last winter, as the US hospital system became overwhelmed with COVID-19 cases related to the Omicron strain, facilities across the country were forced to postpone elective surgeries to free up hospital beds. Similar to what happened following the initial outbreak of the pandemic in 2020, patients are now returning to the operating room to have…
DetailsOn January 27, 2022, the FDA announced its decision to not include Glycopyrrolate on the 503B bulks list. Following this announcement, outsourcing facilities will not be permitted to compound the drug-using bulk API, unless the product appears in the future on the FDA’s drug shortage list. Glycopyrrolate is not currently on the drug shortage list.…
Details